Alumis, Inc. (ALMS)
21.60
+0.20
(+0.93%)
USD |
NASDAQ |
May 29, 16:00
21.60
0.00 (0.00%)
After-Hours: 20:00
Alumis EPS Diluted (Quarterly) : -0.7441 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Nektar Therapeutics | -1.815 |
| Bristol Myers Squibb Co. | 1.308 |
| Amylyx Pharmaceuticals, Inc. | -0.3734 |
| Aardvark Therapeutics, Inc. | -0.9896 |
| Johnson & Johnson | 2.141 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -93.05M |
| Revenue (Quarterly) | 1.741M |
| Total Expenses (Quarterly) | 94.79M |
| Enterprise Value | 2.266B |
| Gross Profit Margin (Quarterly) | 49.97% |
| Profit Margin (Quarterly) | -5.34K% |
| Earnings Yield | -8.89% |
| Normalized Earnings Yield | -8.230 |